Erasca (ERAS) Cash & Equivalents (2020 - 2026)
Erasca (ERAS) reported Cash & Equivalents of $47.3 million for Q1 2026, down 32.95% on a YoY basis from $70.5 million in Q1 2025, and down 35.97% quarter-over-quarter from $73.8 million in Q4 2025.
Erasca (ERAS) Cash & Equivalents (2020 - 2026) Analysis & Trends
Erasca has reported Cash & Equivalents for 7 years, with the latest figure at $47.3 million in Q1 2026.
- For the quarter ending Q1 2026, Cash & Equivalents fell 32.95% year-over-year to $47.3 million; the trailing twelve-month figure through Mar 2026 stood at $47.3 million (down 32.95% YoY), and the FY2025 full-year result was $73.8 million, up 8.95% from the prior year.
- Cash & Equivalents for Q1 2026 stood at $47.3 million, down from $73.8 million in the prior quarter.
- The five-year high for Cash & Equivalents was $333.3 million in Q1 2022, with the low at $47.3 million in Q1 2026.
- Historically, Cash & Equivalents has averaged $146.1 million across 5 years, with a median of $112.9 million in 2023.
- Annual changes were most pronounced in 2022 — Cash & Equivalents jumped 96.1% — and 2023, when it slumped 67.25%.
- Erasca's Cash & Equivalents stood at $284.2 million in 2022, then tumbled by 67.25% to $93.1 million in 2023, then fell by 27.22% to $67.7 million in 2024, then increased by 8.95% to $73.8 million in 2025, then sank by 35.97% to $47.3 million in 2026.
- The last three Cash & Equivalents figures came in at $47.3 million (Q1 2026), $73.8 million (Q4 2025), and $70.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 32.30 Mn |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 1.91 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 286.70 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 2.77 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | 18.44 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 7.15 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 5.49 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 558.94 Mn |
| 10 | Erasca | 4.28 Bn | 4.03 Bn | - | 47.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 47.26 Mn |
| Dec 31, 2025 | 73.81 Mn |
| Sep 30, 2025 | 70.23 Mn |
| Jun 30, 2025 | 66.14 Mn |
| Mar 31, 2025 | 70.48 Mn |
| Dec 31, 2024 | 67.74 Mn |
| Sep 30, 2024 | 68.89 Mn |
| Jun 30, 2024 | 172.80 Mn |
| Mar 31, 2024 | 172.80 Mn |
| Dec 31, 2023 | 93.08 Mn |
| Sep 30, 2023 | 112.86 Mn |
| Jun 30, 2023 | 138.79 Mn |
| Mar 31, 2023 | 272.76 Mn |
| Dec 31, 2022 | 284.22 Mn |
| Sep 30, 2022 | 219.26 Mn |
| Jun 30, 2022 | 219.26 Mn |
| Mar 31, 2022 | 333.35 Mn |
| Dec 31, 2021 | 360.49 Mn |
| Sep 30, 2021 | 445.81 Mn |
| Jun 30, 2021 | 156.40 Mn |